KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Receivables (2016 - 2025)

Biomarin Pharmaceutical's Change in Receivables history spans 17 years, with the latest figure at $120.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 266.34% year-over-year to $120.7 million, compared with a TTM value of $228.1 million through Dec 2025, up 293.81%, and an annual FY2025 reading of $228.1 million, up 293.81% over the prior year.
  • Change in Receivables for Q4 2025 was $120.7 million at Biomarin Pharmaceutical, up from -$48.7 million in the prior quarter.
  • The five-year high for Change in Receivables was $138.8 million in Q1 2023, with the low at -$72.5 million in Q4 2024.
  • Average Change in Receivables over 5 years is $24.6 million, with a median of $25.6 million recorded in 2021.
  • Year-over-year, Change in Receivables tumbled 293.25% in 2021 and then soared 46462.3% in 2022.
  • Tracing BMRN's Change in Receivables over 5 years: stood at -$61000.0 in 2021, then soared by 46462.3% to $28.3 million in 2022, then surged by 106.83% to $58.5 million in 2023, then plummeted by 224.02% to -$72.5 million in 2024, then skyrocketed by 266.34% to $120.7 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Change in Receivables are $120.7 million (Q4 2025), -$48.7 million (Q3 2025), and $98.5 million (Q2 2025).